RAKOVINA THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.09 CAD | -5.26% |
|
+12.50% | +5.88% |
| Apr. 09 | Rakovina Therapeutics Presents At American Association Of Cancer Research Annual Meeting | MT |
| 2023 | Rakovina Therapeutics Announces Appointment to Scientific Advisory Board | MT |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 12.57M 17.29M |
|---|---|---|---|---|---|
| Net income 2021 | -5M -6.88M | Net income 2022 | -2M -2.75M | EV / Sales 2021 | - |
| Net cash position 2021 | 2.81 3.87 | Net cash position 2022 | 0.9 1.23 | EV / Sales 2022 | - |
| P/E ratio 2021 |
-2.14
x | P/E ratio 2022 |
-4.5
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 54.28% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -5.26% | ||
| 1 week | +12.50% | ||
| Current month | -10.00% | ||
| 1 month | +20.00% | ||
| 3 months | -10.00% | ||
| 6 months | -18.18% | ||
| Current year | +5.88% |
1 week
0.09
0.10
1 month
0.070.14
Current year
0.010.14
1 year
0.010.16
3 years
0.010.30
5 years
0.000.40
10 years
0.000.40
| Managers | Title | Age | Since |
|---|---|---|---|
Mads Daugaard
PSD | President | - | 20-12-31 |
David Hyman
DFI | Director of Finance/CFO | - | - |
John Langlands
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 57 | 19-05-05 | |
Jeffrey Bacha
CHM | Chairman | 56 | 20-11-30 |
Dennis Brown
BRD | Director/Board Member | 74 | 21-03-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 0.09 | -5.26% | 55,000 |
| 24-04-16 | 0.095 | +5.56% | 61,000 |
| 24-04-15 | 0.09 | 0.00% | 50,000 |
| 24-04-12 | 0.09 | +5.88% | 93,000 |
| 24-04-11 | 0.085 | +6.25% | 10,000 |
Delayed Quote Toronto S.E., April 17, 2024 at 03:59 pm EDT
More quotes
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is engaged in advancing cancer therapies based on deoxyribonucleic acid (DNA)-damage response technologies. The Company has a pipeline of DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials and obtain marketing approval for cancer therapeutics. The Companyâs research programs include kt-2000, kt-3000 and kt-4000. The kt-2000 next generation PARP-inhibitors. The kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating DNA double-strand (DSB) repair mechanisms while enhancing PARP inhibitor activity. The kt-4000 series lead candidates release a potent methylation agent causing damage to a tumor cellâs DNA while also inhibiting DNA-damage repair mechanisms to cancer cell death.
Calendar
2024-04-25
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +5.88% | 4.57M | |
| -3.39% | 102B | |
| +2.61% | 96.84B | |
| -0.44% | 21.48B | |
| -18.14% | 20.82B | |
| -7.73% | 18.6B | |
| -40.70% | 16.81B | |
| -26.89% | 13.78B | |
| +1.12% | 13.4B | |
| +22.25% | 11.06B |
- Stock Market
- Equities
- RKV Stock
